Clinical Analysis Of Adjuvant Endocrine Therapy For Premenopausal Women With Hormone Receptor Positive Early Breast Cancer

Breast cancer is the most common malignant tumor in women,which seriously threatens women's health.Normal mammary epithelial cells contain estrogen,progesterone receptors and other receptors.They were divided into hormone dependent and non hormone dependent in term of the growth and proliferation of cancer cells are regulated by hormones or not.In the context of endocrine therapy,the treatment of tamoxifen for 5 years has been a standard treatment for premenopausal patients.In recent years,however,this standard has been challenged.Many large randomized clinical trials have provided new options for adjuvant endocrine therapy in premenopausal patients.Summarizing and analyzing the latest domestic and foreign literature on adjuvant endocrine therapy for premenopausal women with hormone receptor positive early breast cancer by China How Net,Quan Fang database,Pub Med document retrieval platform,I will make a review comprehensively.And collecting clinical and pathological data of 196 cases of patients with breast cancer in the First Affiliated Hospital of Bengbu Medical College from January 2012 to January 2014,based on the criteria,in accordance with the terms of the total of 147 cases,including69 cases of ER+/PR+ subtype breast cancer(experimental group)and 78 cases of ER+/PR-subtype breast cancer(control group).Comprehensively analyse and compare two groups of breast cancer patients on clinical and pathological features,tamoxifen sensitivity and the differences of prognosis,we can study the effects of the different expression of PR on the clinical and prognostic of patients with hormone receptor positive early breast cancer.Compared with chi square test,the disease-free survival rate was calculated with the Kaplan-Merie method and the survival curves were compared with Log-rank test.According to this study,we can conclude that compared to ER+/PR+ breast cancer,ER+/PR-subtype breast cancer usually has larger diameter,more lymph node metastasis,and the positive rate of Ki-67 is high,HER-2 usually expressed positive.In addition,ER+/PR-subtype breast cancer has worse response to tamoxifen than ER+/PR+ breast cancer,the disease-free survival(DFS)and over survival(OS)of the patients with ER+/PR-subtype breast cancer were poorer than the patients with ER+/PR+ subtype breast cancer.